U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Programmed death ligand-1 (PD-L1) blocking antibody response

MedGen UID:
1004012
•Concept ID:
CN322753
•
Sign or Symptom
Synonyms: Anti-PDL1 response; Programmed Death Ligand-1 Blocker response
Drug:
Programmed death ligand-1 (PD-L1) blocking antibody
MedGen UID:
1778085
•Concept ID:
C4475435
•
Pharmacologic Substance
Programmed death ligand-1 (PD-L1) blocking antibody

Professional guidelines

PubMed

Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1.
Vugmeyster Y, Grisic AM, Wilkins JJ, Loos AH, Hallwachs R, Osada M, Venkatakrishnan K, Khandelwal A
Cancer Chemother Pharmacol 2022 Oct;90(4):369-379. Epub 2022 Sep 6 doi: 10.1007/s00280-022-04468-6. PMID: 36066618Free PMC Article
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Ning YM, Suzman D, Maher VE, Zhang L, Tang S, Ricks T, Palmby T, Fu W, Liu Q, Goldberg KB, Kim G, Pazdur R
Oncologist 2017 Jun;22(6):743-749. Epub 2017 Apr 19 doi: 10.1634/theoncologist.2017-0087. PMID: 28424325Free PMC Article

Recent clinical studies

Etiology

Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, Lin J, Zhang J, Zhu W, Jia H, Qin L, Lu L, Chen J
Hepatology 2021 Nov;74(5):2544-2560. Epub 2021 Aug 25 doi: 10.1002/hep.31921. PMID: 34036623
Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.
Chandrasekaran D, Sundaram S, N K, R P
Asian Pac J Cancer Prev 2019 Oct 1;20(10):2951-2957. doi: 10.31557/APJCP.2019.20.10.2951. PMID: 31653140Free PMC Article
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T
Nature 2018 Feb 22;554(7693):544-548. Epub 2018 Feb 14 doi: 10.1038/nature25501. PMID: 29443960Free PMC Article
Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A, Tselikas L, de Baere T, Houot R
Ann Oncol 2017 Dec 1;28(suppl_12):xii33-xii43. doi: 10.1093/annonc/mdx683. PMID: 29253115
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE-087
J Clin Oncol 2017 Jul 1;35(19):2125-2132. Epub 2017 Apr 25 doi: 10.1200/JCO.2016.72.1316. PMID: 28441111Free PMC Article

Diagnosis

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K
Mol Cancer 2022 Jan 21;21(1):28. doi: 10.1186/s12943-021-01489-2. PMID: 35062949Free PMC Article
Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy.
He L, Wang L, Wang Z, Li T, Chen H, Zhang Y, Hu Z, Dimitrov DS, Du J, Liao X
J Med Chem 2021 Nov 11;64(21):15716-15726. Epub 2021 Nov 3 doi: 10.1021/acs.jmedchem.1c00961. PMID: 34730979
Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, Lin J, Zhang J, Zhu W, Jia H, Qin L, Lu L, Chen J
Hepatology 2021 Nov;74(5):2544-2560. Epub 2021 Aug 25 doi: 10.1002/hep.31921. PMID: 34036623
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C, Liu R, Wang B, Lian J, Yao Y, Sun H, Zhang C, Fang L, Guan X, Shi J, Han S, Zhan F, Luo S, Yao Y, Zheng T, Zhang Y
J Immunother Cancer 2021 Jan;9(1) doi: 10.1136/jitc-2020-001895. PMID: 33462141Free PMC Article
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS
Nature 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011. PMID: 25428504Free PMC Article

Therapy

An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
LaMarche NM, Hegde S, Park MD, Maier BB, Troncoso L, Le Berichel J, Hamon P, Belabed M, Mattiuz R, Hennequin C, Chin T, Reid AM, Reyes-Torres I, Nemeth E, Zhang R, Olson OC, Doroshow DB, Rohs NC, Gomez JE, Veluswamy R, Hall N, Venturini N, Ginhoux F, Liu Z, Buckup M, Figueiredo I, Roudko V, Miyake K, Karasuyama H, Gonzalez-Kozlova E, Gnjatic S, Passegué E, Kim-Schulze S, Brown BD, Hirsch FR, Kim BS, Marron TU, Merad M
Nature 2024 Jan;625(7993):166-174. Epub 2023 Dec 6 doi: 10.1038/s41586-023-06797-9. PMID: 38057662Free PMC Article
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K
Mol Cancer 2022 Jan 21;21(1):28. doi: 10.1186/s12943-021-01489-2. PMID: 35062949Free PMC Article
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C, Liu R, Wang B, Lian J, Yao Y, Sun H, Zhang C, Fang L, Guan X, Shi J, Han S, Zhan F, Luo S, Yao Y, Zheng T, Zhang Y
J Immunother Cancer 2021 Jan;9(1) doi: 10.1136/jitc-2020-001895. PMID: 33462141Free PMC Article
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T
Nature 2018 Feb 22;554(7693):544-548. Epub 2018 Feb 14 doi: 10.1038/nature25501. PMID: 29443960Free PMC Article
PD-1/PD-L1 Pathway in Breast Cancer.
Schütz F, Stefanovic S, Mayer L, von Au A, Domschke C, Sohn C
Oncol Res Treat 2017;40(5):294-297. Epub 2017 Mar 27 doi: 10.1159/000464353. PMID: 28346916

Prognosis

An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
LaMarche NM, Hegde S, Park MD, Maier BB, Troncoso L, Le Berichel J, Hamon P, Belabed M, Mattiuz R, Hennequin C, Chin T, Reid AM, Reyes-Torres I, Nemeth E, Zhang R, Olson OC, Doroshow DB, Rohs NC, Gomez JE, Veluswamy R, Hall N, Venturini N, Ginhoux F, Liu Z, Buckup M, Figueiredo I, Roudko V, Miyake K, Karasuyama H, Gonzalez-Kozlova E, Gnjatic S, Passegué E, Kim-Schulze S, Brown BD, Hirsch FR, Kim BS, Marron TU, Merad M
Nature 2024 Jan;625(7993):166-174. Epub 2023 Dec 6 doi: 10.1038/s41586-023-06797-9. PMID: 38057662Free PMC Article
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K
Mol Cancer 2022 Jan 21;21(1):28. doi: 10.1186/s12943-021-01489-2. PMID: 35062949Free PMC Article
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C, Liu R, Wang B, Lian J, Yao Y, Sun H, Zhang C, Fang L, Guan X, Shi J, Han S, Zhan F, Luo S, Yao Y, Zheng T, Zhang Y
J Immunother Cancer 2021 Jan;9(1) doi: 10.1136/jitc-2020-001895. PMID: 33462141Free PMC Article
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L, Liu Y, Wang Y
Oncologist 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05. PMID: 30819829Free PMC Article
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS
Nature 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011. PMID: 25428504Free PMC Article

Clinical prediction guides

An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
LaMarche NM, Hegde S, Park MD, Maier BB, Troncoso L, Le Berichel J, Hamon P, Belabed M, Mattiuz R, Hennequin C, Chin T, Reid AM, Reyes-Torres I, Nemeth E, Zhang R, Olson OC, Doroshow DB, Rohs NC, Gomez JE, Veluswamy R, Hall N, Venturini N, Ginhoux F, Liu Z, Buckup M, Figueiredo I, Roudko V, Miyake K, Karasuyama H, Gonzalez-Kozlova E, Gnjatic S, Passegué E, Kim-Schulze S, Brown BD, Hirsch FR, Kim BS, Marron TU, Merad M
Nature 2024 Jan;625(7993):166-174. Epub 2023 Dec 6 doi: 10.1038/s41586-023-06797-9. PMID: 38057662Free PMC Article
Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.
Sordo-Bahamonde C, Lorenzo-Herrero S, Granda-Díaz R, Martínez-Pérez A, Aguilar-García C, Rodrigo JP, García-Pedrero JM, Gonzalez S
Mol Cancer 2023 Aug 30;22(1):142. doi: 10.1186/s12943-023-01845-4. PMID: 37649037Free PMC Article
Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z, Wu X
Cancer Med 2020 Nov;9(21):8086-8121. Epub 2020 Sep 2 doi: 10.1002/cam4.3410. PMID: 32875727Free PMC Article
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L, Liu Y, Wang Y
Oncologist 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05. PMID: 30819829Free PMC Article
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS
Nature 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011. PMID: 25428504Free PMC Article

Recent systematic reviews

The present roles and future perspectives of Interleukin-6 in biliary tract cancer.
Zhou M, Na R, Lai S, Guo Y, Shi J, Nie J, Zhang S, Wang Y, Zheng T
Cytokine 2023 Sep;169:156271. Epub 2023 Jun 16 doi: 10.1016/j.cyto.2023.156271. PMID: 37331095
Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
Cheng Y, Wang C, Wang Y, Dai L
Future Oncol 2022 Jan;18(2):261-273. Epub 2021 Dec 7 doi: 10.2217/fon-2021-0641. PMID: 34874185
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Chang E, Pelosof L, Lemery S, Gong Y, Goldberg KB, Farrell AT, Keegan P, Veeraraghavan J, Wei G, Blumenthal GM, Amiri-Kordestani L, Singh H, Fashoyin-Aje L, Gormley N, Kluetz PG, Pazdur R, Beaver JA, Theoret MR
Oncologist 2021 Oct;26(10):e1786-e1799. Epub 2021 Jul 27 doi: 10.1002/onco.13887. PMID: 34196068Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...